探讨慢性乙型肝炎患者抗病毒治疗过程中血清HBeAg定量动态变化对治疗应答的预测价值(2)
 |
| 第1页 |
参见附件。
[2] 张缭云，赵龙凤，石少媛，张金叶. 人类白细胞抗原-DRB1基因多态性与阿德福韦酯抗病毒近期疗效的相关性[J]. 山西医科大学学报. 2010(05)
[3] 吴娜，苏菲，张振华，夏国美，张婷婷，张玲，郜玉峰，李旭. 拉米夫定治疗慢性乙型肝炎的疗效及其预测因素分析[J]. 实用肝脏病杂志. 2010(01)
[4] 陈黎，耿高璞，张金良，刘熙荣. 替比夫定联合苦参素治疗HBeAg阳性慢性乙型肝炎临床观察[J]. 云南中医中药杂志. 2009(03)
[5] Fried，M，Liaw，Y-F，Luo，K.Role of baseline and on-treatment quantitative HBeAg levels in predicting response to Peginterferon alfa-2a (40kD) (Pegasys) monotherapy in a large， multinational trial of patients with chronic hepatitis B. Hepatology . 2008
[6] 庄鹏，曾惠琼，王湘郴，范紫香，姚秋萍，吴正林. 替比夫定治疗HBeAg阳性慢性乙型肝炎的近期疗效观察[J]. 中国热带医学. 2010(11)
[7] NH Park，JW Shin，JH Park，SJ Bang，DH Kim，KR Joo.Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. Journal of Viral Hepatitis . 2009
[8] Heijtink RA，Janssen HL，Hop WC，et al.Interferon-alpha therapy in chronic hepatitis B：early monitoring of HBeAg may help to decide whether to stop or prolong therapy. Journal of Viral Hepatitis . 2000
您现在查看是摘要介绍页，详见PDF附件。